Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

[News]

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

More... (http://www.news-medical.net/news/20130518/Boehringer-Ingelheim-updates-HCPs-patients-on-COMBIVENT-RESPIMAT-Inhalation-Spray.aspx)